These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2512129)

  • 1. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.
    Schaad UB; Wedgwood-Krucko J; Guenin K; Buehlmann U; Kraemer R
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):858-65. PubMed ID: 2512129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.
    Schaad UB; Wedgwood-Krucko J; Suter S; Kraemer R
    J Pediatr; 1987 Oct; 111(4):599-605. PubMed ID: 3309236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis.
    Schaad UB; Wedgwood J; Ruedeberg A; Kraemer R; Hampel B
    Pediatr Infect Dis J; 1997 Jan; 16(1):106-11; discussion 123-6. PubMed ID: 9002119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
    Griese M; Müller I; Reinhardt D
    Eur J Med Res; 2002 Feb; 7(2):79-80. PubMed ID: 11891148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1990 Mar; 34(3):487-8. PubMed ID: 2110438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group.
    Richard DA; Nousia-Arvanitakis S; Sollich V; Hampel BJ; Sommerauer B; Schaad UB
    Pediatr Infect Dis J; 1997 Jun; 16(6):572-8. PubMed ID: 9194107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].
    Prévotat A; Leroy S; Perez T; Wallet F; Wallaert B
    Rev Mal Respir; 2010 May; 27(5):449-56. PubMed ID: 20569877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.
    Vic P; Ategbo S; Turck D; Husson MO; Tassin E; Loeuille GA; Deschildre A; Druon D; Elian JC; Arrouet-Lagandre C; Farriaux JP
    Eur J Pediatr; 1996 Nov; 155(11):948-53. PubMed ID: 8911895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient undergoing allogeneic hematopoietic stem cell transplantation].
    Kawazoe H; Takiguchi Y; Inoue T; Yamaguchi K; Tanaka H; Kaji M; Tsuji S; Ninomiya M; Fukuoka N; Ohnishi H; Ishida T; Houchi H
    Yakugaku Zasshi; 2008 Apr; 128(4):657-61. PubMed ID: 18379184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.
    Aronoff SC; Klinger JD
    Antimicrob Agents Chemother; 1984 Feb; 25(2):279-80. PubMed ID: 6561954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
    Rappaz I; Decosterd LA; Bille J; Pilet M; Bélaz N; Roulet M
    Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Azlocillin treatment of Pseudomonas aeruginosa bronchopulmonary infections in children with cystic fibrosis].
    Grenier B; Gilly R
    Presse Med; 1984 Mar; 13(13):815-8. PubMed ID: 6231602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
    McGrath BJ; Bailey EM; Lamp KC; Rybak MJ
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2741-6. PubMed ID: 1482142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis.
    Riethmueller J; Junge S; Schroeter TW; Kuemmerer K; Franke P; Ballmann M; Claass A; Broemme S; Jeschke R; Hebestreit A; Staab D; Koetz K; Doering G; Stern M
    Infection; 2009 Oct; 37(5):418-23. PubMed ID: 19756419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.
    Giamarellou H; Bassaris HP; Petrikkos G; Busch W; Voulgarelis M; Antoniadou A; Grouzi E; Zoumbos N
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3264-71. PubMed ID: 11083625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits.
    Bayer AS; Lam K; Norman D; Kim KS; Morrison JO
    Chemotherapy; 1985; 31(5):351-61. PubMed ID: 3931992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.